{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:26:57Z","timestamp":1777865217337,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhep.2026.01.022","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:59:05Z","timestamp":1770796745000},"page":"855-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the tumour's Achilles heel: ATR inhibition to exploit a constitutive vulnerability of hepatoblastoma"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0883-579X","authenticated-orcid":false,"given":"Nina","family":"Desboeufs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-3637","authenticated-orcid":false,"given":"Achim","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.01.022_bib1","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA replication stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2026.01.022_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jhep.2025.11.023","article-title":"Targeting ATR to overcome cisplatin resistance in hepatoblastoma","volume":"84","author":"Morel-Ribeiro","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.022_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5582\/bst.2023.01311","article-title":"An update on diagnosis and treatment of hepatoblastoma","volume":"17","author":"Cao","year":"2024","journal-title":"Biosci Trends"},{"key":"10.1016\/j.jhep.2026.01.022_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1535-7163.MCT-23-0094","article-title":"Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models","volume":"23","author":"Pusch","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2026.01.022_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1706837","article-title":"The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis","volume":"15","author":"Su","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2026.01.022_bib6","series-title":"WHO classification of tumours: digestive system tumours","first-page":"240","article-title":"Hepatoblastoma","author":"Saxena","year":"2019"},{"key":"10.1016\/j.jhep.2026.01.022_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-025-00620-7","article-title":"Hepatoblastoma","volume":"11","author":"Pio","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhep.2026.01.022_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29763","article-title":"Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States","volume":"69","author":"Kahla","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jhep.2026.01.022_bib9","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","article-title":"Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer","volume":"11","author":"Hirsch","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2026.01.022_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.01.022_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2026.01.022_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-biochem-072324-031915","article-title":"DNA damage and replication stress checkpoints","volume":"94","author":"Yates","year":"2025","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jhep.2026.01.022_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.01.022_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41580-020-0257-5","article-title":"The plasticity of DNA replication forks in response to clinically relevant genotoxic stress","volume":"21","author":"Berti","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2026.01.022_bib15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhep.2026.01.022_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/modpathol.2013.80","article-title":"Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"Lopez-Terrada","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2026.01.022_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113583","article-title":"Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival","volume":"200","author":"Pire","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2026.01.022_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2026.01.022_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:56:57Z","timestamp":1777528617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0168827826000644"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the tumour's Achilles heel: ATR inhibition to exploit a constitutive vulnerability of hepatoblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.11.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}